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617Abstracts
modeling based corrections might be necessary for 
which the (re)-building of the study model is required.
Univariate sensitivity analysis seems appropriate for 
identiﬁcation of the most important adjustments. If not
all relevant study parameters can be substituted with
country speciﬁc ones, multivariate or probabilistic sensi-
tivity analysis appears to be a promising way to quantify
the uncertainty associated with a transfer. If study results
cannot be transferred, the transfer of study models or
designs should be investigated as this can save a sub-
stantial amount of time when conducting a new study.
CONCLUSIONS: The transferability decision chart is a
transparent and user-friendly tool for evaluating and
improving the transferability of economic evaluation
results. For the assessment of transferability, a detailed
method description in the original study is necessary. In
addition, the relevant data should be presented in a non-
aggregated manner for enabling modeling adjustment.
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OBJECTIVES: In making decisions about which health
care interventions to reimburse, cost-effectiveness analy-
ses should directly compare all relevant treatment 
alternatives based on all available data. “Head-to-head”
clinical trials directly comparing all treatment alternatives
are seldom available, requiring the use of indirect trial evi-
dence to make the required comparisons. We illustrate the
use of formal methods to make such comparisons using
two recent cost-effectiveness analyses commissioned for
the National Institute for Clinical Excellence (NICE).
METHODS: The clinical trial evidence available to
inform the evaluations consisted of a mixed set of com-
parisons, such as drugs A vs. B , B vs. C, A vs. D. The
model parameters required to perform the required direct
comparison of the drugs (A vs. B. vs. C.) were estimated
jointly from the available data using a generalized linear
model in a Bayesian hierarchical framework. This was
implemented using Markov Chain Monte Carlo tech-
niques. RESULTS: Direct comparisons of 9 anti-epilepsy
drugs and 5 drugs for the acute-manic episode in bipolar
disorder were undertaken based on data from 27 and 7
trials, respectively. In epilepsy, the analysis showed that,
above a cost-effectiveness threshold of £20,000 per
QALY, the newer adjunct therapies were likely to be cost-
effective, although there was considerable uncertainty in
these results. In bipolar disorder, olanzapine was cost-
effective above a threshold of £7000 per responder. The
use of this analytical approach avoided the need to restrict
the analysis solely to the pairwise treatment comparisons
made in existing trials. Cost-effectiveness acceptability
curves were derived which incorporate the additional
uncertainty associated with the observed heterogeneity
between trials. CONCLUSIONS: The use of formal
analysis of mixed treatment comparisons is likely to play
an important role in reimbursement decisions. Further
research is needed into how additional uncertainty asso-
ciated with unobserved heterogeneity can be incorporated
into cost-effectiveness models.
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OBJECTIVE: To estimate actual use of beneﬁt/risk and
beneﬁt/cost outcomes in health systems decision making.
METHODS: Respondents were selected from public and
private payers, provider organizations, technology ﬁrms,
regulatory agencies and universities in France, Sweden,
UK and US. A survey questionnaire was developed and
pre-tested with 15 people. After modiﬁcation, the survey
was administered to 116 selected people. We asked about
actual use, and examples, by them and their organization
of results from beneﬁt/risk and beneﬁt/cost evaluations in
making decisions on acceptance or rejection of new, and
delisting current, health care technologies. RESULTS: A
total of 104 (89.7%) respondents completed the survey.
Every organization clearly used beneﬁt/risk results in
making decisions about accepting, using, rejecting and
deleting technologies. Surprisingly, nearly every organi-
zation also used economic outcomes to help make deci-
sions. Such results may not have always been formal
beneﬁt/cost evaluations (i.e., about 50% used budget
impact primarily) but there was at the least the recogni-
tion about making trade-offs of beneﬁts and costs among
alternatives. CONCLUSIONS: These results are contrary
to other published studies, based mainly on opinions and
perceptions that found little use of economic analysis in
health care decision making. Post hoc studies of actual
decisions made in UK, Australia of formal analyses, and
in Canada of less formal methods, conﬁrmed use of
beneﬁt/cost results. Measuring actual behavior on use of
economic outcome evaluations in health care decision
making provides different answers than soliciting 
opinions and perceptions of others’ use of these results.
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